Leukemia and Lymphoma Society
The Leukemia & Lymphoma Society is the fastest-growing voluntary health organization with a nationwide presence. The Society's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and to improve the quality of life of patients and their families. Since its founding in 1949, the Society has provided more than $240 million for research specifically targeting blood-related cancers.
The Society's strategic goals are: To accelerate the acquisition and application of scientific understanding, to advance the treatment, diagnosis, or prevention of leukemia, lymphoma, Hodgkin's lymphoma and myeloma; to reach all patients at the time of diagnosis and make a significant difference in the lives of all who choose to receive the Society's services; to increase influence with private and public organizations to achieve the Society's strategic outcomes; to maximize the revenue we raise in the near term while, at the same time, developing capabilities for revenue growth that extend over a longer time period; to increase awareness of the Society among the general public and core constituents in order to increase support for our mission and reach more people with the services we provide; and to become the nonprofit agency of choice for staff and volunteers.
For more information, or to contact Leukemia and Lymphoma Society, see their website at: www.leukemia.org
» Recent News
Patients and Caregivers Can Now Interact with Leading Experts in Myeloma Research
02 Jun 04 | Leading researchers will present the latest information about the treatment of multiple myeloma as part of The Leukemia & Lymphoma Society's free educational program, Myeloma: The Latest Treatment Options.
Four Young Leukemia Patients Inducted into National Soccer Hall of Fame's Walk of Fame
18 Nov 03 | Jackson Alea, Nickolaus Bedwell, Christopher Melkonian and Brandon Zammit have loved soccer so much, they didn't let anything stand in the way of the game - including their battle with leukemia.
Join More than 12,000 Schools Teaching the Value of Community Service through School & Youth Programs; New Web Site Makes Registration Easy
30 Jul 03 | In the 2002-03 school year, 6 million students from more than 12,000 schools across the US participated in The Leukemia & Lymphoma Society's School & YouthSM Programs, raising $10.5 million to find cures for leukemia, lymphoma and myeloma.
Verizon Employees Raised More Than $480,000 Through Light The Night Walk; Funds Support Leading-Edge Blood Cancer Researcher
21 Jul 03 | One step at a time, Verizon employees are directly and positively impacting the lives of patients with leukemia, lymphoma and myeloma. More than 2,000 employees took part in The Leukemia & Lymphoma Society's Light The Night® Walk last year.
Telephone Education Program Addresses Side Effects from Treatment for Chronic Myelogenous Leukemia (CML)
15 Jul 03 | The Leukemia & Lymphoma Society is offering a free telephone education workshop in conjunction with CancerCare entitled, "Living with CML: Managing the Side Effects."
New Non-Hodgkin Lymphoma Treatment Approved by the U.S. Food and Drug Administration
30 Jun 03 | The U.S. Food and Drug Administration today approved Bexxar® for the treatment of patients with CD20 positive, follicular, non-Hodgkin lymphoma who are resistant to Rituxan® (rituximab) and have relapsed following chemotherapy.
U.S. Sen. Kay Bailey Hutchison's Stewardship Benefits Blood Cancer Patients and their Families
27 Jun 03 | The Leukemia & Lymphoma Society extends its gratitude to U.S. Sen. Kay Bailey Hutchison (R-TX) for securing $5 million to bring vital education services to blood cancer patients and their families.
Medicare Reform Packages Debated on Capitol Hill Must Include Balanced Approach to Reimbursement for Cancer Treatment
24 Jun 03 | The Leukemia & Lymphoma Society today joined other cancer organizations in expressing deep concern about proposed changes to cancer care being debated by the U.S. House of Representatives and Senate in the context of Medicare reform.
Cancer Drug Velcade™ Holds Promise for a Novel Treatment of Mantle Cell Lymphoma
20 Jun 03 | New research found that Millennium Pharmaceutical's cancer drug, Velcade (bortezomib), recently approved for the treatment of multiple myeloma, blocks growth and kills mantle cell lymphoma (MCL) cells in the laboratory setting.
"Lymphoma and the Older Patient," a Free Telephone Education Program, Informs Patients of Leading-Edge Lymphoma Research
13 Jun 03 | The Leukemia & Lymphoma Society is offering a free telephone education workshop entitled "Lymphoma and the Older Patient" in conjunction with CancerCare.
The Leukemia & Lymphoma Society Welcomes New England Journal of Medicine Findings on Treatment of Advanced Hodgkin Lymphoma
12 Jun 03 | The Leukemia & Lymphoma Society welcomes findings published in the June 12 issue of the New England Journal of Medicine, which determined that radiotherapy did not improve the outcomes of patients with advanced Hodgkin lymphoma.
The Leukemia & Lymphoma Society Announces Free Telephone Education Program on the Latest Advances in the Treatment of Chronic Myelogenous Leukemia
06 Jun 03 | The Leukemia & Lymphoma Society, the leading source of information and support for patients and families battling blood cancer, is offering a free telephone education workshop entitled, "The Pace of Progress: Latest Advances in CML."
Free Improving the Chemotherapy Experience Teleconference Series Offers Tips and Strategies to Help People Get Through Treatment
22 May 03 | More than half the people diagnosed with cancer in this country are treated with chemotherapy. While every patient's experience is different, today many of the side effects of chemotherapy can be prevented or minimized.